Amgen beats expectations but its stock price still drops

Amgen shares fell in premarket trading after hitting a record high, despite strong Q4 earnings and raised 2026 guidance. Wall Street offered mixed views; TD Cowen lifted its target to $420, while Morgan Stanley and Citi maintained cautious ratings with implied downside. The stock reaction follows a recent rally and mixed analyst sentiment on future growth prospects.